Pacific Biosciences of California Inc reports results for the quarter ended September 30 - Earnings Summary

• Pacific Biosciences of California Inc PACB.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -22 cents. The mean expectation of ten analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -18 cents to -12 cents per share.

• Revenue fell 3.8% to $38.44 million from a year ago; analysts expected $40.21 million.

• Pacific Biosciences of California Inc's reported EPS for the quarter was a loss of 13 cents​.

• The company reported a quarterly loss of $38 million.

• Pacific Biosciences of California Inc shares had risen by 56.3% this quarter and gained 9.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $1.65, about 21.2% below its last closing price of $2.00

This summary was machine generated from LSEG data November 5 at 10:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)